Riverbridge Partners LLC lowered its position in Glaukos Corporation (NYSE:GKOS – Free Report) by 19.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 433,228 shares of the medical instruments supplier’s stock after selling 101,941 shares during the period. Glaukos comprises approximately 1.1% of Riverbridge Partners LLC’s holdings, making the stock its 28th largest position. Riverbridge Partners LLC’s holdings in Glaukos were worth $46,641,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. AQR Capital Management LLC raised its position in Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the last quarter. Jones Financial Companies Lllp grew its position in Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after purchasing an additional 67,668 shares during the period. M&T Bank Corp acquired a new position in Glaukos in the second quarter valued at $203,000. Finally, Gamco Investors INC. ET AL raised its holdings in shares of Glaukos by 10.7% in the second quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier’s stock valued at $826,000 after buying an additional 773 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other Glaukos news, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $143.35, for a total value of $243,695.00. Following the sale, the director owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. The trade was a 7.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director owned 35,528 shares in the company, valued at $5,000,921.28. The trade was a 12.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 41,273 shares of company stock worth $5,832,003 in the last three months. 5.90% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on Glaukos
Glaukos Stock Up 3.0%
Shares of Glaukos stock opened at $135.09 on Wednesday. Glaukos Corporation has a one year low of $73.16 and a one year high of $148.11. The company has a market cap of $7.93 billion, a P/E ratio of -41.19 and a beta of 0.82. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.73 and a current ratio of 5.43. The firm has a fifty day moving average of $126.03 and a two-hundred day moving average of $117.52.
Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.12. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The business had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. The business’s quarterly revenue was up 41.2% compared to the same quarter last year. On average, analysts forecast that Glaukos Corporation will post -0.57 earnings per share for the current year.
About Glaukos
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Read More
- Five stocks we like better than Glaukos
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
